-
公开(公告)号：US11008550B2
公开(公告)日：2021-05-18
申请号：US16250366
申请日：2019-01-17
Applicant: BioNTech AG , TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg Universitat Mainz Gemeinnutzige GmbH
Inventor： Ugur Sahin , Marco Poleganov , Tim Beissert
Abstract: The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
-
公开(公告)号：US10717780B2
公开(公告)日：2020-07-21
申请号：US16117197
申请日：2018-08-30
Applicant: Biontech AG , Ganymed Pharmaceuticals GmbH , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
Inventor： Ugur Sahin , Ozlem Türeci , Christiane Stadler , Julia Holland , Hayat Bähr-Mahmud , Tim Beissert , Laura Plum , Fabrice Le Gall , Arne Jendretzki , Markus Fiedler
Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
-
公开(公告)号：US10550430B2
公开(公告)日：2020-02-04
申请号：US15031415
申请日：2014-10-24
Applicant: Biontech AG , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gemeinnutzige GmbH
Inventor： Ugur Sahin , Michael Schäfer , Marta Magdalena Faryna , Tana Omokoko , Lisa Hebich , Petra Simon , Annett Reichardt , Özlem Öz
IPC: C12Q1/68 , C07H21/04 , C12Q1/6881 , C12Q1/6876
Abstract: The present invention relates to a kit and a method for determining whether a subject shows an immune response against an antigen.
-
公开(公告)号：US10526387B2
公开(公告)日：2020-01-07
申请号：US15341528
申请日：2016-11-02
Applicant: BioNTech AG
Inventor： Thorsten Klamp , Ugur Sahin , Ozlem Tureci , Michael Koslowski , Thomas Hiller , Jens Schumacher
IPC: C07K14/47 , A61K39/00 , C07K14/005 , C12N7/00
Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
-
55.发明申请公开(公告)号：US20190309067A1
公开(公告)日：2019-10-10
申请号：US16335373
申请日：2017-09-20
Applicant: BIONTECH AG , Astellas Pharma Inc.
Inventor： Ugur Sahin , Christiane Stadler , Leyla Fischer , Arne Jendretzki , Özlem Türeci , Fabrice Le Gall , Maria Kreuzberg
Abstract: The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
-
Patent Agency Ranking
公开(公告)号：US20190194623A1
公开(公告)日：2019-06-27
申请号：US16250366
申请日：2019-01-17
Applicant: BioNTech AG , TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg Univers
Inventor： Ugur Sahin , Marco Poleganov , Tim Beissert
IPC: C12N5/074
CPC classification number: C12N5/0696 , C12N2510/00
Abstract: The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
-
公开(公告)号：US10253373B2
公开(公告)日：2019-04-09
申请号：US15591896
申请日：2017-05-10
Applicant: BioNTech AG , Johannes Gutenberg-Universität Mainz
Inventor： Ugur Sahin , Özlem Türeci , Michael Koslowski
IPC: C12Q1/68 , C12Q1/6886 , C07K14/47 , C07K16/30
Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
-
58.发明申请公开(公告)号：US20190062762A1
公开(公告)日：2019-02-28
申请号：US16143520
申请日：2018-09-27
Applicant: BioNTech AG
Inventor： Ugur Sahin , Silke Holtkamp , Ozlem Tureci , Sebastian Kreiter
Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
-
公开(公告)号：US20180177885A1
公开(公告)日：2018-06-28
申请号：US15895402
申请日：2018-02-13
Applicant: BioNTech AG
Inventor： Ozlem Tureci , Ugur Sahin , Sebastian Kreiter
CPC classification number: A61K47/64 , A61K48/00 , C07K14/4748 , C07K14/70539 , C07K2319/02 , C07K2319/03
Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
-
60.发明申请MODIFICATION OF RNA, PRODUCING AN INCREASED TRANSCRIPT STABILITY AND TRANSLATION EFFICIENCY 审中-公开RNA的修饰，产生增加的转录稳定性和翻译效率公开(公告)号：US20170009244A1
公开(公告)日：2017-01-12
申请号：US15217555
申请日：2016-07-22
Applicant: BioNTech AG
Inventor： Ugur Sahin , Silke Holtkamp , Ozlem Tureci , Sebastian Kreiter
Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
Abstract translation: 本发明的目的是提供具有增加的稳定性和翻译效率的RNA以及获得这种RNA的手段。 通过在基因治疗方法中使用所述RNA可以获得更高等级的表达。
-
-
-
-
-
-
-
-
-
Search Results
66
records
(took 0.036 seconds)
